Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

Activating FLT3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) associate with inferior outcomes. We determined that pacritinib, a JAK2/FLT3 inhibitor, has in vitro activity against FLT3-ITD and tyrosine kinase domain (TKD) mutations. Therefore, we conducted a phase...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Invest New Drugs
Main Authors: Jeon, Jae Yoon, Zhao, Qiuhong, Buelow, Daelynn R., Phelps, Mitch, Walker, Alison R., Mims, Alice S., Vasu, Sumithira, Behbehani, Gregory, Blachly, James, Blum, William, Klisovic, Rebecca B., Byrd, John C., Garzon, Ramiro, Baker, Sharyn D., Bhatnagar, Bhavana
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858927/
https://ncbi.nlm.nih.gov/pubmed/31102119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00786-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares